Roivant Sciences Ltd.

Overview

• Bermuda-registered biopharmaceutical company that advances the development and commercialization of medicines through independently managed subsidiaries called "Vants."
• Incubates discovery-stage biopharma and health-technology companies.
• Centralizes capital allocation and shared services at the Roivant level while decentralizing operations to the Vants to enable faster decision making and focused execution.

Pipeline and product candidates (selected highlights)

Brepocitinib (lead asset)

• Indications: Dermatomyositis (DM); non-infectious uveitis (NIU); also in development for cutaneous sarcoidosis (CS) and lichen planopilaris (LPP)
• Vant: Priovant
• Modality: Small molecule JAK1/TYK2 inhibitor
• Regulatory status: NDA accepted by FDA with Priority Review; PDUFA date targeted for Q3 2026
• Commercial expectations: Potential U.S. launch in DM by end of September 2026 if approved; topline data for NIU Phase 3 expected in 2H 2026; Phase 2/3 in CS and LPP planned

IMVT-1402 (FcRn inhibitor)

• Indications: IgG-mediated autoimmune diseases, including Graves’ disease (GD), difficult-to-treat RA (D2T RA), Sjögren’s disease (SjD), myasthenia gravis (MG), CIDP, CLE
• Vant: Immunovant
• Modality: Fully human monoclonal antibody
• Regulatory status: Multiple Phase 2/3 programs; topline data anticipated in 2H 2026

Mosliciguat (sGC activator)

• Indication: Pulmonary hypertension associated with interstitial lung disease (PH-ILD)
• Vant: Pulmovant
• Modality: Inhaled, once-daily therapy
• Regulatory status: Phase 2 (PH-ILD); topline data expected 2H 2026

Genevant (RNA delivery platforms)

• Focus: LNP and GalNAc ligand conjugate technologies for nucleic acid therapeutics
• Modality: Nucleic acid delivery platforms; collaboration-based model
• Ownership: Roivant basic ownership 83% (64% fully diluted)

Other Vants and portfolio notes

• Includes Covant and Arbutus (patent/licensing connections)
• Dermavant was sold to Organon in October 2024

Corporate highlights and financial snapshot (as of March 31, 2026)

• Cash and liquidity: Consolidated cash, cash equivalents and marketable securities of approximately $4.3 billion
• Accumulated deficit: Approximately $501.8 million
• Profitability outlook: The company states it expects to incur substantial operating losses in the foreseeable future and may not achieve sustained profitability
• Employees: Approximately 721 full-time employees across Roivant and its subsidiaries (about 659 in the United States)
• Share repurchases: Two-authorized repurchase tranches totaling up to $2.5 billion (a $1.0 billion authorization plus a prior $1.5 billion program exhausted by June 30, 2025); repurchased about 24.0 million common shares for approximately $314.9 million in the 12 months ended March 31, 2026
• Dermavant transaction: Completed with Organon in October 2024; Roivant received $183.6 million upfront plus a $75 million milestone payment following FDA approval of VTAMA in January 2025. Former Dermavant equity holders are eligible for pro rata milestone payments up to $950 million and tiered royalties on VTAMA net sales

Vant ownership (as of March 31, 2026)

• Priovant: 72% basic (66% fully diluted)
• Immunovant: 56% basic (52% fully diluted)
• Pulmovant: 97% basic (90% fully diluted)
• Genevant: 83% basic (64% fully diluted)
• Covant: 94% basic (91% fully diluted)
• Arbutus: 20% basic (13% or 19% depending on dilution note)
• Roivant retains certain rights to future milestones and royalties across these Vants

Licensing and collaboration framework

• Priovant–Pfizer: Exclusive global license to brepocitinib and TYK2 programs for human and animal uses; includes milestones, royalties, and sales-based payments between Priovant and Pfizer
• Immunovant–HanAll: Exclusive rights to batoclimab/IMVT-1402 and related antibodies outside the HanAll Territory; termination and other provisions per agreement
• Pulmovant–Bayer: Exclusive global rights to mosliciguat with milestones and royalties
• Genevant–Arbutus: Cross-license arrangements for LNP and GalNAc technologies; royalties payable on net receipts

Operating model

• Vant model: Independently managed Vants focus on a single or a small set of programs, each with its own management team and equity incentives
• Central functions: Roivant centralizes financing, strategy, and shared services to support the Vants’ development and potential commercialization
• Intellectual property: Relies on in-licensed patents, patent families and trade secrets; maintains a mix of exclusive licenses and cross-licenses with partners
• Manufacturing: Does not own manufacturing facilities; relies on contract manufacturing organizations (CMOs) and plans to scale through CMOs as candidates approach regulatory approval

Financial and business risks

• Maintains a substantial cash position but faces ongoing capital needs for development, in-licensing, and acquisitions
• Exposed to regulatory and clinical trial risk, including dependence on trial outcomes and approvals
• Faces strategic risks associated with the Vant structure, including decentralization, potential dilution, and governance complexities
• Collaboration terms and milestone outcomes affect future cash flow and development timelines

Summary

Roivant builds and operates a family of Vants to discover, develop, and potentially commercialize immune- and cardiopulmonary-focused therapies, using a centralized capital framework and a diversified pipeline that includes brepocitinib (JAK1/TYK2 inhibitor) in DM and NIU (Priovant), IMVT-1402 (FcRn inhibitor) in Immunovant, mosliciguat (inhaled sGC activator) in Pulmovant, and Genevant’s RNA-delivery platforms. As of March 31, 2026, the company reported roughly 721 full-time employees (659 in the U.S.), approximately $4.3 billion in cash and marketable securities, and an accumulated deficit of about $501.8 million. The company has a track record of prior regulatory approvals and completed late-stage programs, including the Dermavant disposition with Organon in 2024. Near-term catalysts include the brepocitinib NDA and multiple program data readouts planned for 2026 and beyond.